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Summary
Survival from melanoma is influenced by several, well-established clinical and
histopathological factors, e.g. age, Breslow thickness and microscopic ulceration.
We (the Section of Epidemiology and Biostatistics, University of Leeds) have car-
ried out research to better understand the biological basis for these observations.
Preliminary results indicated a protective role for vitamin D in melanoma relapse
and that higher vitamin D was associated with thinner primary melanomas.
Funding from the British Skin Foundation enabled JNB to establish a study of the
effects of vitamin A in melanoma. The results suggested that vitamin A could
reduce the protective effect of vitamin D in terms of overall survival. Therefore,
we propose that vitamin D3 supplementation alone might be preferable to com-
bined multivitamin preparations, where vitamin D supplementation is deemed to
be appropriate.
Proving a causal link between vitamin D and melanoma-specific survival is chal-
lenging. We have shown limited evidence of causation in a Mendelian randomi-
zation experiment (described in more detail later). Recent work in Leeds has also
shown that higher vitamin D may be protective for microscopic ulceration. Taken
together, vitamin D appears to be associated with less aggressive primary melano-
mas and may itself influence outcome. We continue to explore the role of vita-
min D in melanoma survival and the optimum levels that might be crucial.
What’s already known about this topic?
• Vitamin D has been reported to have anti-proliferative effects in several cancers.
• Higher vitamin D is associated with thinner primary melanomas and a reduced risk
of relapse.
• Vitamin A has been shown to antagonise vitamin D in animal models.
What does this study add?
• Vitamin A levels may reduce the protective effect of vitamin D on overall survival
in patients diagnosed with melanoma.
• We propose supplementation of vitamin D3 alone in preference to multivitamins or
cod liver oil, where appropriate.
• Higher vitamin D may be protective for microscopic ulceration and it is associated
with less aggressive primary melanomas at a gene expression level.
In 2000, we (the Section of Epidemiology and Biostatistics,
University of Leeds) started a research programme, which was
intended to explore the factors associated with survival among
melanoma patients. Several histopathological factors have been
shown to be prognostic and, as such, have been utilized in
the AJCC staging system:1 namely Breslow thickness, the pres-
ence of mitoses (for thin tumours, defining stage IB) and
ulceration status. However, additional histopathological char-
acteristics exist, which have been employed by other staging
systems, including the presence of tumour-infiltrating
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lymphocytes (TILs)2 and vascular invasion. Although sentinel
node biopsy provides further prognostic information3 (which
is modest taking into account all other known prognostic fac-
tors),4 it has no established value in terms of improving sur-
vival from melanoma. Apart from histopathological measures,
clinical factors, e.g. tumour site, sex5 and age also have a role
in determining outcome from melanoma, with male sex, older
age at diagnosis and a truncal site (compared to limbs) being
particularly hazardous. The underlying basis for ulceration,
sex, age and site being associated with a poorer survival is not
yet fully understood but these observations are clearly telling
us something important about the role of the host in mela-
noma survival.
In an attempt to carry out research designed to increase our
understanding of these tantalizing observations, in 2000 we
started to build very large data and sample sets from mela-
noma patients. The largest of these is the Leeds Melanoma
Cohort, consisting of 2184 population-ascertained melanoma
patients for which the median follow up is now 7 years.
The second dataset was a smaller case-control study
designed to identify hypotheses: comparing cases (melanoma
patients at late relapse, a median of 8 years after diagnosis)
with controls (melanoma patients who had survived at least
5 years without relapse). The rationale was that environmental
factors could play a role in recurrence and that a comparison
between late relapsers (people whose melanoma cells had by
definition been relatively quiescent for many years) with non-
relapsers, might help to identify some of these elements. In
2005, an analysis of the exposure data (which had been col-
lected by questionnaire in the case-control study) revealed that
patients who had not relapsed were more likely to have been
taking vitamin D supplements than those who had progressive
disease. Sixty-two (42%) of 149 non-relapsers and 28 (31%)
of 91 relapsers reported regular intake of supplemental vita-
min D 1 year before interview (OR 06; 95% CI, 04 to 11; P
0.09).6
Although this was a small, retrospective study, it was
nonetheless an interesting observation and formed the basis of
the hypothesis that vitamin D might have a role in melanoma
survival. This was consistent with previous reports indicating
that vitamin D was anti-proliferative for several types of cancer
in vitro,7 including melanoma.8 Several hypotheses regarding
the mode of action of vitamin D in cancer had been postu-
lated, including non-genomic mechanisms, i.e. non-vitamin D
receptor-mediated. However, vitamin D receptor (VDR) sig-
nalling is also plausible. A recent article reported that VDR sig-
nalling led to downregulation of one of the master
transcription factors for cell division, FOXM1, and reduced
growth of pancreatic ductal adenocarcinoma.9
We therefore went on to look at serum 25-OH vitamin
D2/3 levels shortly after diagnosis in relation to survival in a
much larger sample from the Leeds Melanoma Cohort. This
study of 872 patients, reported in 2009,6 showed that higher
vitamin D levels were associated with thinner tumours. Higher
vitamin D levels were also independently protective for relapse
from melanoma. Vitamin D levels have now been measured
for the entire Leeds Melanoma Cohort (n = 2184, as afore-
mentioned, the median follow-up is now 7 years). Figure 1
shows the survival rates for participants, stratified by vitamin
D levels, and illustrates the melanoma-specific survival advan-
tage that remains for patients with higher vitamin D levels at
diagnosis.
These two observations made in our retrospective and
cohort studies suggested a role for vitamin D in melanoma
survival. However, many diseases have been reported to be
associated with low vitamin D levels and there has been wide-
spread scepticism about whether or not these relationships are
in fact causal. These associations could be indicative of reverse
causality. Vitamin D levels are higher in leaner, fitter people
so that the sceptical case is that that higher vitamin D levels
may merely be acting as a marker of a healthier lifestyle.
Moreover, supplementation trials have generally shown dis-
appointing results, although a meta-analysis of supplementa-
tion for all causes (i.e. given for any condition) did show a
survival benefit.10 Since 2009, our group has been working to
explore whether or not there is a causal relationship between
vitamin D and melanoma survival and we will return to that
below.
Whilst we pursued causality, JNB sought funding from the
British Skin Foundation (BSF) for a study of vitamin A in mel-
anoma patients. Vitamin D signals through the vitamin D
Fig. 1. Kaplan-Meier survival curve by serum vitamin D levels for the
Leeds Melanoma Cohort Study. Note. This study shows differences in
melanoma-specific survival, stratified by serum vitamin D levels at
diagnosis using a 25 nmol/L cut-off point. The vitamin D levels
presented here were adjusted for seasonality; serum vitamin D levels
were linearly regressed on season (Jan–Mar, Apr–Jun, Jul–Sep, Oct–
Dec) and batch. Levels were adjusted to blood levels as if the sample
had been drawn during the winter months (Oct–Dec). Survival
estimates were censored at 14 years. Logistic regression was used to
adjust for sample batch and season. Participants with a vitamin D level
above 25 nmol/L in these circumstances were shown to be less likely
to die from their melanoma.
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receptor (VDR) to mediate its genomic effects, although non-
genomic effects have also been described by Deeb.11 The VDR
however forms a heterodimer with the retinoic acid receptor,
RXR, to which a derivative of vitamin A binds. We were
aware of reports that vitamin A antagonises the effects of vita-
min D in animal models 12 and the BSF grant sought funds to
test this in the Leeds Melanoma Cohort. In this study of 795
cases,13 serum vitamin A levels were measured and analysed
for association with Breslow thickness, overall (OS) and mela-
noma-specific survival (MSS), and modification of the effect of
vitamin D levels on survival. The protective effect of vitamin
D on OS was reduced in patients with high vitamin A levels
(≥ 22 lmol/l)(HR = 099, 95% CI (072,136), P = 093)
compared to patients with low levels (< 22 lmol)(HR =
077, 95% CI (064, 093), P = 0007), although the differ-
ence was not statistically significant (P = 026). Our conclu-
sion was that higher vitamin A levels may reduce the
protective effect of vitamin D, although the study was likely
underpowered to see a definitive effect. Sub-optimal levels of
vitamin D are common in temperate climates, and are usually
managed by dietary supplementation, but vitamin A is rarely
insufficient. Based on the data from the BSF funded study, we
suggested that vitamin D3 supplementation alone might be
preferable for melanoma patients than preparations containing
both vitamins D and A, if supplementation seemed appropri-
ate. In practice, this means vitamin D3 alone rather than cod
liver oil or multivitamins.
The work we have done to explore whether there is a cau-
sal relationship between higher vitamin D levels and better
melanoma survival started with an experiment known as Men-
delian randomization. In this approach, inherited genetic vari-
ation, which moderates the factor under test, is sought and an
association with that gene and the outcome of interest is
tested. If a relationship between inheritance of that genetic
variation and outcome is seen then this is good evidence that
the relationship is causal (see Fig. 2a). In our experiment, we
looked at the inheritance of a single nucleotide polymorphism
(SNP) coding for the vitamin D binding hormone, which had
been identified in genome-wide association studies as the SNP
with the strongest association with vitamin D levels 14,15 and
has been shown in our data to be so.16 People with this vari-
ant have lower serum levels of vitamin D. If vitamin D were
important for melanoma survival then we would expect peo-
ple inheriting this SNP would have a worse prognosis. We
worked with colleagues from a melanoma research consortium
called BioGenoMEL to carry out a meta-analysis of data from
multiple studies and showed supportive evidence for this
hypothesis, although not quite conclusive.17 In fact only 4%
of the variance in vitamin D levels in the cohort were
‘explained’ by this genetic variation,16 so despite recruiting
several thousand patients, our study was inadequately powered
to show a clear result. This is a common problem with
Mendelian randomization.
The most recent work was based on gene expression (tran-
scriptomic) data from primary melanomas stored from the
Leeds Melanoma Cohort participants. The primary aim of ini-
tial studies was to understand the biological basis of micro-
scopic ulceration: a marker of poor outcome and a possible
marker of intra-tumoural inflammation. Although the signifi-
cance of ulceration is strong enough to merit incorporation
into the AJCC staging system, what it means biologically was
unclear. It seems likely that the role of ulceration is important,
supported by some evidence from an EORTC adjuvant trial
which showed that only patients with ulcerated primaries
(a) (b)
Fig. 2. (a) illustrates how Mendelian randomization can be applied to assess whether or not a causal relationship exists between vitamin D (X)
and survival (Y). Arrows highlight proposed dependency between variables. The rs2282679 SNP (G) is considered a candidate for this assessment,
as it is independent of lifestyle and other confounders. (b) shows a forest plot of the hazard ratios for overall survival in the 8 cohorts (separately
and combined) based on the GC haplotype. Cox proportional hazards models were used to generate estimates (adjusted for age, sex, site and
Breslow thickness).
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appeared to benefit from treatment with pegylated interferon18
despite the observation that overall it is a poor prognostic fac-
tor. We had reported previously that ulcerated tumours have a
more vascular stroma, rich in macrophages,19 suggesting the
possibility that the ulcerated milieu is protumourigenic,
predisposing to inflamed tumours. We therefore looked at the
gene expression patterns associated with ulceration in a Leeds
test set and in two validation sets from Leeds and Lund.20 We
saw that ulceration was associated with upregulation of the
pro-inflammatory cytokines IL-6 and IL-8. A pathway analysis
was suggestive of a wound healing response, bolstering our
hypothesis that inflammation is a key driver of ulcerated
tumours. There is strong evidence in the literature that vitamin
D levels are inversely correlated with c-reactive protein levels
(CRP),21 although there is controversy about the precise
mechanism. Therefore, we decided to examine the relation-
ship between vitamin D levels in the blood and ulceration.
We also investigated whether or not co-morbidities, which
are known to be associated with systemic inflammation (such
as diabetes mellitus, smoking and obesity), were more com-
mon in participants with ulcerated tumours. The findings con-
firmed this suspicion, suggesting that ulceration may be
driven by systemic inflammation, but higher vitamin D levels
were independently protective for ulceration.22
So, this first transcriptomic study, combined with the epi-
demiological investigation reported subsequently, suggests that
vitamin D may be protective for microscopic ulceration. This
is still an association and not proof that higher vitamin D
levels are causally related to better survival but biologically
consistent with weak previous data suggesting that vitamin D
may reduce inflammatory markers.23,24
We then argued that there would be stronger evidence of
causality if serum vitamin D levels at diagnosis were associated
with less aggressive biological subtypes of melanoma, espe-
cially if the genes differentially expressed were in pathways
known to be downstream of the vitamin D receptor. Although
research is ongoing, some preliminary evidence has indicated
that higher vitamin D levels are associated with a lower proba-
bility of higher-grade tumours25: that is that higher vitamin D
levels appeared to be associated with less aggressive tumours
at a gene expression level.
In summary then, we and now others26 have shown that
higher vitamin D levels at diagnosis are associated with thin-
ner primary melanomas. In addition, we and others have
shown a relationship to outcome.27,28 We have reported some
evidence from a Mendelian randomization experiment of a
causal effect for vitamin D and melanoma survival. This was
not unequivocal: we probably needed many thousands of mel-
anoma cases to generate conclusive results. Funding from the
BSF enabled us to report evidence that higher vitamin A levels
in the blood appeared to reduce the protective effect of vita-
min D. We have reported evidence that higher vitamin D
levels are protective for ulceration and are associated with
lower grade tumours. We are building evidence for a causal
relationship between low levels of vitamin D and poorer mela-
noma survival. We continue to work on tumour
transcriptomics and vitamin D and to consider the levels of
vitamin D that appear to be critical.
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